10:26 AM EST, 11/14/2024 (MT Newswires) -- Immutep ( IMMP ) shares were up more than 11% in recent Thursday trading after the company reported positive data from the phase 1 trial evaluating eftilagimod alpha, also known as efti, in combination with Keytruda and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.

The company said the trial's overall survival and progression-free survival data, with a minimum follow-up of almost two years, exceeded expectations and all evaluable patients to date also demonstrated "significant improvement" in overall response rate.

The combination therapy also continued to demonstrate a favorable safety profile, Immutep ( IMMP ) added.

Immutep ( IMMP ) said the phase 1 trial is nearing the completion of its patient enrollment, with additional data updates expected in 2025.

Price: 2.08, Change: +0.21, Percent Change: +11.23